Gabrielle Zuniga

Gabrielle Zuniga

Auto-generated profile, based on publicly available information

Gabrielle Zuniga

Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases, University of Texas Health San Antonio

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2016 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
BYBitna Yi
Bitna Yi
JSJames J. Sahn
James J. Sahn
PAPooneh Memar Ardestani
Pooneh Memar Ardestani
AEAndrew K. Evans
Andrew K. Evans
LSLuisa L. Scott
Luisa L. Scott
MSMehrdad Shamloo
Mehrdad Shamloo
Accumulating evidence suggests that modulating the sigma 2 receptor (Sig2R) can provide beneficial effects for neurodegenerative diseases. Herein, we report the identification of a novel class of Sig2R ligands and their cellular andin vivoactivity in experimental models of Alzheimer's disease (AD). We report thatSAS‐0132 andDKR‐1051, selective ligands of Sig2R, modulate intracellular Ca2+levels in humanSK‐N‐SHneuroblastoma cells. The Sig2R ligandsSAS‐0132 andJVW‐1009 are neuroprotective in aC. elegansmodel of amyloid precursor protein‐mediated neurodegeneration. Since this neuroprotective effect is replicated by genetic knockdown and knockout ofvem‐1, the ortholog of progesterone receptor membrane component‐1 (PGRMC1), these results suggest that Sig2R ligands modulate aPGRMC1‐related pathway. Last, we demonstrate thatSAS‐0132 improves cognitive performance both in the Thy‐1hAPPLond/Swe+transgenic mouse model ofADand in healthy wild‐type mice. These results demonstrate that Sig2R is a promising therapeutic target for neurocognitive disorders includingAD. image

17 October 2021 in Progress in Neurobiology
Verified
Journal Article
Open access
PRPaulino Ramirez
Paulino Ramirez
GZGabrielle Zuniga
Gabrielle Zuniga
WSWenyan Sun
Wenyan Sun
ABAdrian Beckmann
Adrian Beckmann
EOElizabeth Ochoa
Elizabeth Ochoa
BFBess Frost
Bess Frost
Transposable elements comprise almost half of the mammalian genome. A growing body of evidence suggests that transposable element dysregulation accompanies brain aging and neurodegenerative disorders, and that transposable element activation is neurotoxic. Recent studies have identified links between pathogenic forms of tau, a protein that accumulates in Alzheimer’s disease and related “tauopathies,” and transposable element-induced neurotoxicity. Starting with transcriptomic analyses, we find that age- and tau-induced transposable element activation occurs in the mouse brain. Among transposable elements that are activated at the RNA level in the context of brain aging and tauopathy, we find that the endogenous retrovirus (ERV) class of retrotransposons is particularly enriched. We show that protein encoded by Intracisternal A-particle, a highly active mouse ERV, is elevated in brains of tau transgenic mice. Using two complementary approaches, we find that brains of tau transgenic mice contain increased DNA copy number of transposable elements, raising the possibility that these elements actively retrotranspose in the context of tauopathy. Taken together, our study lays the groundwork for future mechanistic studies focused on transposable element regulation in the aging mouse brain and in mouse models of tauopathy and provides support for ongoing therapeutic efforts targeting transposable element activation in patients with Alzheimer’s disease.

13 April 2022 in Alzheimer's & Dementia
Verified
Journal Article
Open access
GZGabrielle Zuniga
Gabrielle Zuniga
SLSimon Levy
Simon Levy
PRPaulino Ramirez
Paulino Ramirez
JMJasmine De Mange
Jasmine De Mange
EGElias Gonzalez
Elias Gonzalez
BFBess Frost
Bess Frost
Introduction: While brains of patients with Alzheimer's disease and related tauopathies have evidence of altered RNA processing, we lack a mechanistic understanding of how altered RNA processing arises in these disorders and if such changes are causally linked to neurodegeneration.Methods: Using Drosophila melanogaster models of tauopathy, we find that overall activity of nonsense‐mediated mRNA decay (NMD), a key RNA quality‐control mechanism, is reduced. Genetic manipulation of NMD machinery significantly modifies tau‐induced neurotoxicity, suggesting that deficits in NMD are causally linked to neurodegeneration. Mechanistically, we find that deficits in NMD are a consequence of aberrant RNA export and RNA accumulation within nuclear envelope invaginations in tauopathy. We identify a pharmacological activator of NMD that suppresses neurodegeneration in tau transgenic Drosophila, indicating that tau‐induced deficits in RNA quality control are druggable.Discussion: Our studies suggest that NMD activators should be explored for their potential therapeutic value to patients with tauopathies.

1 April 2020 in Current Opinion in Neurobiology
Verified
Journal Article
Closed access
ETElizabeth Ochoa Thomas
Elizabeth Ochoa Thomas
GZGabbe Zuniga
Gabbe Zuniga
WSWenyan Sun
Wenyan Sun
BFBess Frost
Bess Frost

1 July 2020 in Cell Reports
Verified
Journal Article
Open access
RMRebekah Mahoney
Rebekah Mahoney
ETElizabeth Ochoa Thomas
Elizabeth Ochoa Thomas
PRPaulino Ramirez
Paulino Ramirez
HMHenry Miller
Henry Miller
ABAdrian Beckmann
Adrian Beckmann
BFBess Frost
Bess Frost
Synaptic activity-induced calcium (Ca2+) influx and subsequent propagation into the nucleus is a major way in which synapses communicate with the nucleus to regulate transcriptional programs important for activity-dependent survival and memory formation. Nuclear Ca2+ shapes the transcriptome by regulating cyclic AMP (cAMP) response element-binding protein (CREB). Here, we utilize a Drosophila model of tauopathy and induced pluripotent stem cell (iPSC)-derived neurons from humans with Alzheimer's disease to study the effects of pathogenic tau, a pathological hallmark of Alzheimer's disease and related tauopathies, on nuclear Ca2+. We find that pathogenic tau depletes nuclear Ca2+ and CREB to drive neuronal death, that CREB-regulated genes are over-represented among differentially expressed genes in tau transgenic Drosophila, and that activation of big potassium (BK) channels elevates nuclear Ca2+ and suppresses tau-induced neurotoxicity. Our studies identify nuclear Ca2+ depletion as a mechanism contributing to tau-induced neurotoxicity, adding an important dimension to the calcium hypothesis of Alzheimer's disease.

28 February 2024 in medRxiv
Verified
Preprint
Open access
PDF file
ASA. Campbell Sullivan
A. Campbell Sullivan
GZGabrielle Zuniga
Gabrielle Zuniga
PRPaulino Ramirez
Paulino Ramirez
RFRoman Fernandez
Roman Fernandez
CWChen-Pin Wang
Chen-Pin Wang
BFBess Frost
Bess Frost
Retrotransposons are viral-like DNA sequences that constitute approximately 41% of the human genome. Studies in Drosophila, mice, cultured cells, and human brain indicate that retrotransposons are activated in settings of tauopathy, including Alzheimer’s disease, and causally drive neurodegeneration. The anti-retroviral medication 3TC (lamivudine), a nucleoside analog reverse transcriptase inhibitor, limits retrotransposon activation and suppresses neurodegeneration in tau transgenic Drosophila, two mouse models of tauopathy, and in brain assembloids derived from patients with sporadic Alzheimer’s disease. We performed a 24-week phase 2a open-label clinical trial of 300 mg daily oral 3TC ( NCT04552795 ) in 12 participants aged 52-83 years with a diagnosis of mild cognitive impairment due to suspected Alzheimer’s disease. Primary outcomes included feasibility, blood brain barrier penetration, effects of 3TC on reverse transcriptase activity in the periphery, and safety. Secondary outcomes included changes in cognition and fluid-based biomarkers of neurodegeneration and neuroinflammation. All participants completed the six-month trial; one event of gastrointestinal bleeding due to a peptic ulcer was reported. 3TC was detected in blood and cerebrospinal fluid (CSF) of all participants, suggestive of adherence to study drug and effective brain penetration. Cognitive measures remained stable throughout the study. Glial fibrillary acidic protein (GFAP) ( P =0.03) and Flt1 ( P =0.05) were significantly reduced in CSF over the treatment period; Aβ42/40 ( P =0.009) and IL-15 ( P =0.006) were significantly elevated in plasma. While this is an open label study of small sample size, the significant decrease of some neurodegeneration- and neuroinflammation-related biomarkers in CSF, significantly elevated levels of plasma Aβ42/40, and a trending decrease of CSF NfL after six months of 3TC exposure suggest a beneficial effect on subjects with mild cognitive impairment due to suspected Alzheimer’s disease. Feasibility, safety, tolerability, and central nervous system (CNS) penetration assessments further support clinical evaluation of 3TC in a larger placebo-controlled, multi-dose clinical trial.